Remove Blogging Remove Journal Remove San Diego Remove Screening
article thumbnail

Ostendo Raising Funds to Advance Virtual Reality Display Technology

Xconomy

Ostendo Technologies, a Carlsbad, CA-based company founded in 2005 to advance curved screens and other innovative display technologies, has raised $41.8 Adding to the confusion, the most-recent MoneyTree Report on San Diego venture capital activity shows that Ostendo raised almost $10 million in VC funding during the second quarter.

article thumbnail

Interview with Vince Bianco, Newsforce

socalTECH

San Diego-based Newsforce (www.newsforce.com) is a startup which is looking to take advantage of the hunger of the newspaper and media business for revenue, and has created a product which takes press releases and commercial content, and inserts them onto news sites in "sponsored content" blocks. Have you had any issues with that here?

News 124
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How Will Apple Innovate Beyond the iPhone 7? With Next-Gen Siri

Xconomy

According to the Wall Street Journal, PFWTMs (“people familiar with the matter”) say the new device will look pretty much the same as the iPhone 6s. It was the first device to feature both a phone-sized touchscreen and a new interface that made the screen intuitive and delightful to use. Apple’s iPhone 7 is due out next month.

article thumbnail

63 Los Angeles Entrepreneurs To Be Proud Of

SoCal Delicious

Charlie Capen is co-founder of HowToBeADad.com , an entertainment site and dad blog for “parents, soon-to-be parents and people who have no desire to procreate, whatsoever.” Heather McPhaul is the founder of AgingGal.com , a funny little blog about aging and other inconveniences. She just spoke at TED EX in San Diego.

article thumbnail

Bio Roundup: Hope for Lungs, Bradner’s Complaint, FDA Nods & More

Xconomy

The biggest news this week was in oncology, hands down. Merck showed that its immunotherapy pembrolizumab (Keytruda) might become a common option for many patients newly diagnosed with advanced lung cancer, but the bigger picture is that the field is moving fast.

Pricing 52